The White House said nine pharmaceutical manufacturers have reached agreements with the federal government that it says will provide specified drugs to state Medicaid programs at prices aligned with the lowest prices paid in other developed countries.
The companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. The announcement brings the number of manufacturers with the administration’s “most-favored-nation” pricing agreements to 26, covering 89% of the branded-drug market, according to the White House.
The agreements concern products used to treat conditions including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin disorders and several forms of cancer. The White House did not identify individual medicines, their new prices, the countries used as pricing benchmarks or when specific Medicaid programs will receive the negotiated prices.
Participating companies also committed to invest at least $19.6 billion collectively in U.S. manufacturing in the near term, the administration said. Details on the allocation, timing and form of those investments were not included in the announcement.
Several companies will also contribute active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve, or SAPIR. UCB plans to supply 163 tons of levetiracetam, a seizure medication. Sun Pharma will provide 71.4 tons of clindamycin and 6.75 tons of doxycycline, both antibiotics.
Teva will contribute 45 metric tons of metronidazole, used against certain bacterial and parasitic infections, and 4.8 tons of amlodipine, a treatment for high blood pressure. Astellas will provide 25 kilograms of tacrolimus, an immunosuppressant used to help prevent organ rejection following transplantation.
The White House said the latest deals build on an executive order issued in May 2025 that directed federal agencies to pursue prescription-drug prices comparable with the lowest prices in certain other developed countries. It said agreements had previously been reached with 17 leading drugmakers, including Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie and Regeneron.
The administration also cited its TrumpRx program, launched in February, saying patients had saved more than $700 million on medicines through the platform. It said more than 500,000 seniors without GLP-1 coverage for obesity had generated $216 million in savings during the program’s first two months.
The Council of Economic Advisers estimates the pricing agreements could generate $600 billion in savings over a decade, the White House said. The announcement did not provide an underlying methodology for that estimate.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!